{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:40:04Z","timestamp":1792176004102,"version":"4.4.0"},"update-to":[{"DOI":"10.1002\/14651858.cd003982","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2007,10,17]],"date-time":"2007-10-17T00:00:00Z","timestamp":1192579200000}}],"reference-count":52,"publisher":"Wiley","issue":"1","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd003982.pub2","type":"journal-article","created":{"date-parts":[[2007,10,10]],"date-time":"2007-10-10T12:19:30Z","timestamp":1192018770000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Azathioprine for multiple sclerosis"],"prefix":"10.1002","volume":"2010","author":[{"given":"Ilaria","family":"Casetta","sequence":"first","affiliation":[{"name":"Universita degli Studi di Ferrara; Sezione di Clinica Neurologica; Dip.to di Discipline Medico Chirurgiche della Comunicazione e del Comportamento; Corso della Giovecca, 203 Ferrara Italy 44100"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerardo","family":"Iuliano","sequence":"additional","affiliation":[{"name":"Ospedali Riuniti di Salerno; U.O. Neurologia; Via S. Leonardo Salerno Italy 84100"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graziella","family":"Filippini","sequence":"additional","affiliation":[{"name":"Fondazione I.R.C.C.S. - Istituto Neurologico C.Besta; Neuroepidemiology Unit; via Celoria 11 Milano Italy 20133"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,10,17]]},"reference":[{"key":"10.1002\/14651858.CD003982.pub2-BIB0001|cit1","first-page":"179","article-title":"Double-masked trial of azathioprine in multiple sclerosis","volume":"2","author":"British and Dutch Multiple Sclerosis Azathioprine Trial Group","year":"1988","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD003982.pub2-BIB0002|cit2","doi-asserted-by":"crossref","unstructured":"The British and Dutch Multiple Sclerosis Azathioprine Trial Group Double-blind controlled trial of azathioprine in the treatment of multiple sclerosis Journal of Neurology Neurosurgery and Psychiatry 1987 1387","DOI":"10.1136\/jnnp.50.10.1387"},{"key":"10.1002\/14651858.CD003982.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1212\/WNL.39.8.1018","article-title":"A placebo-controlled, randomized, double-masked, variable dosage, clinical trial of azathioprine with and without methylprednisolone in multiple sclerosis","volume":"39","author":"Ellison","year":"1989","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD003982.pub2-BIB0004|cit4","article-title":"Clinical controlled randomized trial of azathioprine in multiple sclerosis","volume-title":"Recent advances in multiple sclerosis therapy","author":"Ghezzi","year":"1989"},{"key":"10.1002\/14651858.CD003982.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1212\/WNL.41.1.20","article-title":"The efficacy of azathioprine in relapsing-remitting multiple sclerosis","volume":"41","author":"Goodkin","year":"1991","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD003982.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/BF00838165","article-title":"A double blind study on azathioprine efficacy in multiple sclerosis: final report","volume":"240","author":"Milanese","year":"1993","journal-title":"Journal of Neurology"},{"key":"10.1002\/14651858.CD003982.pub2-BIB0007|cit7","first-page":"509","article-title":"Etude de 213 cas de sclerose en plaques traites par l' azathioprine de 1967- a 1982","volume":"139","author":"Aimard","year":"1983","journal-title":"Revue Neurologique"},{"key":"10.1002\/14651858.CD003982.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1111\/j.1600-0404.1971.tb07480.x","article-title":"Therapeutic trial of azathioprine in MS","volume":"47","author":"Cendrowski","year":"1971","journal-title":"Acta Neurologica Scandinavica"},{"key":"10.1002\/14651858.CD003982.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/BF02334050","article-title":"Effectiveness of azathioprine treatment in multiple sclerosis","volume":"9","author":"Fratiglioni","year":"1988","journal-title":"Italian Journal of Neurological Sciences"},{"key":"10.1002\/14651858.CD003982.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(80)92107-8","article-title":"Double-blind controlled trial of immunosuppression in the treatment of Multiple Sclerosis","volume":"2","author":"Mertin","year":"1980","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD003982.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0140-6736(82)90547-5","article-title":"Double-blind Controlled Trial of Immunosuppression in the Treatment of Multiple Sclerosis: Final Report","volume":"2","author":"Mertin","year":"1982","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD003982.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0303-8467(88)80005-2","article-title":"A long-term double-blind controlled study on the effect of azathioprine in the treatment of multiple sclerosis","volume":"90","author":"Minderhoud","year":"1988","journal-title":"Clinical Neurology and Neurosurgery"},{"key":"10.1002\/14651858.CD003982.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/0022-510X(82)90201-5","article-title":"Azathioprine in treatment of multiple sclerosis","volume":"54","author":"Patzold","year":"1982","journal-title":"Journal of the Neurological Sciences"},{"key":"10.1002\/14651858.CD003982.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/BF00313173","article-title":"Azathioprine in Multiple Sclerosis- A 3 year controlled study of its effectiveness","volume":"223","author":"Patzold","year":"1980","journal-title":"Journal of Neurology"},{"key":"10.1002\/14651858.CD003982.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1136\/jnnp.42.4.338","article-title":"Prolonged azathioprine treatment of non-remitting muliptle sclerosis","volume":"42","author":"Rosen","year":"1979","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"key":"10.1002\/14651858.CD003982.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1001\/archneur.1973.00490210090017","article-title":"MS unaffected by azathioprine in pilot study","volume":"28","author":"Silberberg","year":"1973","journal-title":"Archives of Neurology"},{"key":"10.1002\/14651858.CD003982.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/jnnp.36.1.124","article-title":"Long-term treatment of multiple sclerosis with azathioprine","volume":"36","author":"* * Swinburn WR","year":"1973","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"key":"10.1002\/14651858.CD003982.pub2-BIB0018|cit18","first-page":"435","article-title":"Follow-up evaluation after at least two years' treatment with azathioprine in a double-blind trial","volume":"24","author":"Zeeberg","year":"1985","journal-title":"European Neurology"},{"key":"10.1002\/14651858.CD003982.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/978-94-009-4143-4_9","article-title":"Azathioprine Assessment in Progressive Multiple sclerosis. Clinical Aspects","volume-title":"Multiple Sclerosis Research in Europe","author":"Zeeberg","year":"1986"},{"key":"10.1002\/14651858.CD003982.pub2-BIB0020|cit20","unstructured":"The Australian Adverse Drug Reactions Bulletin Drug induced pancreatitis http:\/\/www.tga.gov.au\/adr\/aadrb\/aadr0612.htm#a1 (access January 12 2007) 2006"},{"issue":"4","key":"10.1002\/14651858.CD003982.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1212\/WNL.43.4.831","article-title":"Long-term safety of azathioprine therapy in multiple sclerosis","volume":"43","author":"Amato","year":"1993","journal-title":"Neurology"},{"issue":"6","key":"10.1002\/14651858.CD003982.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/j.1365-2133.2004.06323.x","article-title":"Guidelines for prescribing azathioprine in dermatology","volume":"151","author":"Anstey","year":"2004","journal-title":"British Journal of Dermatolology"},{"issue":"6","key":"10.1002\/14651858.CD003982.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1212\/WNL.46.6.1607","article-title":"Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study","volume":"46","author":"Confavreux","year":"1996","journal-title":"Neurology"},{"issue":"Suppl 6","key":"10.1002\/14651858.CD003982.pub2-BIB0024|cit24","first-page":"vi3","article-title":"Disease evolution in multiple sclerosis","volume":"253","author":"Ebers","year":"2006","journal-title":"Journal of Neurology"},{"key":"10.1002\/14651858.CD003982.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1111\/j.1749-6632.1993.tb35896.x","article-title":"The George Hitchings and Gertrude Elion Lecture. The pharmacology of azathioprine","volume":"685","author":"Elion","year":"1993","journal-title":"Annals of New York Academy of Sciences"},{"key":"10.1002\/14651858.CD003982.pub2-BIB0026|cit26","unstructured":"Higgins JPT Green S Assessment of study quality Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]; Section 6. In: The Cochrane Library, Issue 3, 2005"},{"key":"10.1002\/14651858.CD003982.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jns.2004.04.022","article-title":"Clinical practice of immunosuppressive treatments in MS: results of a second international questionnaire","volume":"223","author":"Hommes","year":"2004","journal-title":"Journal Neurological Science"},{"issue":"8","key":"10.1002\/14651858.CD003982.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1093\/rheumatology\/35.8.738","article-title":"Does exposure to immunosuppressive therapy increase the 10 year malignancy and mortality risks in rheumatoid arthritis? A matched cohort study","volume":"35","author":"M.","year":"1996","journal-title":"British Journal Rheumatology"},{"issue":"1A","key":"10.1002\/14651858.CD003982.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/0002-9343(85)90245-1","article-title":"Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment","volume":"78","author":"Kinlen","year":"1985","journal-title":"American Journal Medicine"},{"issue":"5","key":"10.1002\/14651858.CD003982.pub2-BIB0030|cit30","first-page":"691","article-title":"Secondary myelodysplastic syndromes following treatment with azathioprine are associated with aberrations of chromosome 7","volume":"90","author":"Knipp","year":"2005","journal-title":"Haematologica"},{"key":"10.1002\/14651858.CD003982.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1093\/brain\/awh721","article-title":"The natural history of multiple sclerosis: a geographically based study 9: observations on the progressive phase of the disease","volume":"129","author":"Kremenchutzky","year":"2006","journal-title":"Brain"},{"key":"10.1002\/14651858.CD003982.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"issue":"10","key":"10.1002\/14651858.CD003982.pub2-BIB0033|cit33","first-page":"553","article-title":"Prolonged treatment of multiple sclerosis with average doses of azathioprine. An evaluation of 15 years' experience","volume":"140","author":"Lhermitte","year":"1984","journal-title":"Review Neurology (Paris)"},{"key":"10.1002\/14651858.CD003982.pub2-BIB0034|cit34","unstructured":"Loke YK Price D Herxheimer A Including adverse effects In: Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005]; Appendix 6b. In: The Cochrane Library, Issue 3, 2005"},{"key":"10.1002\/14651858.CD003982.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1212\/WNL.46.4.907","article-title":"Defining the clinical course of multiple sclerosis: results of an international survey. National Multiplosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis","volume":"46","author":"Lublin","year":"1996","journal-title":"Neurology"},{"issue":"12","key":"10.1002\/14651858.CD003982.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1001\/archneur.62.12.1843","article-title":"Efficacy of azathioprine on multiple sclerosis new brain lesions evaluated using magnetic resonance imaging","volume":"62","author":"Massacesi","year":"2005","journal-title":"Archives of Neurology"},{"issue":"1","key":"10.1002\/14651858.CD003982.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1345\/aph.1H219","article-title":"Meta-Analysis of Risk of Malignancy with Immunosuppressive Drugs in Inflammatory Bowel Disease","volume":"41","author":"Masunaga","year":"2007","journal-title":"Annals Pharmacotherapy"},{"key":"10.1002\/14651858.CD003982.pub2-BIB0038|cit38","unstructured":"McCabe CJ Chilcott J Tappenden P O'Hagan A Claxton K Abrams K Problems with the MS Risk sharing scheme British Medical Journal 2003"},{"issue":"7745","key":"10.1002\/14651858.CD003982.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S0140-6736(72)90341-8","article-title":"Oncogenicity of immunosuppressive drugs","volume":"1","author":"McEwan","year":"1972","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD003982.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0140-6736(97)24030-4","article-title":"New treatments and azathioprine in multiple sclerosis","volume":"350","author":"Palace","year":"1997","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD003982.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.jaad.2005.07.059","article-title":"Azathioprine in dermatology: the past, the present, and the future","volume":"55","author":"Patel","year":"2006","journal-title":"Journal of the American Academy of Dermatology"},{"key":"10.1002\/14651858.CD003982.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1002\/ana.410130302","article-title":"New diagnostic criteria for multiple sclerosis: guidelines for research protocols","volume":"13","author":"Poser","year":"1983","journal-title":"Annals Neurology"},{"issue":"3","key":"10.1002\/14651858.CD003982.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1191\/135248506ms1307cr","article-title":"Secondary myelodysplastic syndrome following long-term treatment with azathioprine in patients with multiple sclerosis","volume":"12","author":"Putzki","year":"2006","journal-title":"Multiple Sclerosis"},{"issue":"5","key":"10.1002\/14651858.CD003982.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"694","DOI":"10.7326\/0003-4819-79-5-694","article-title":"Azathioprine","volume":"79","author":"Rosman","year":"1973","journal-title":"Annals of Internal Medicine"},{"key":"10.1002\/14651858.CD003982.pub2-BIB0045|cit45","first-page":"99","article-title":"Clinical and hematologic study of 6[(1-methyl-4-nitro-5-imidazolyl)thio]-purine (B.W.57-322) and related compounds","volume":"14","author":"Rundles","year":"1961","journal-title":"Cancer Chemotherapy Reports"},{"issue":"12","key":"10.1002\/14651858.CD003982.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1136\/ard.47.12.988","article-title":"Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow up study","volume":"47","author":"Silman","year":"1988","journal-title":"Annals Rheumatologic Diseases"},{"issue":"7385","key":"10.1002\/14651858.CD003982.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1136\/bmj.326.7385.388","article-title":"Problems with UK government's risk sharing scheme for assessing drugs for multiple sclerosis","volume":"326","author":"Sudlow","year":"2003","journal-title":"British Medical Journal"},{"issue":"2","key":"10.1002\/14651858.CD003982.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1046\/j.1351-5101.2003.00721.x","article-title":"The risk of cancer from azathioprine as a treatment of multiple sclerosis","volume":"11","author":"Taylor","year":"2004","journal-title":"European Journal of Neurology"},{"key":"10.1002\/14651858.CD003982.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1172\/JCI16432","article-title":"CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD41 T lymphocytes","volume":"111","author":"Tiede","year":"2003","journal-title":"Journal Clinical Investigation"},{"key":"10.1002\/14651858.CD003982.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/brain\/112.1.133","article-title":"The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability","volume":"112","author":"Weinshenker","year":"1989","journal-title":"Brain"},{"issue":"22","key":"10.1002\/14651858.CD003982.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1055\/s-2004-826853","article-title":"Azathioprine-associated myelodysplastic syndrome with cytogenetic aberrations","volume":"129","author":"Willerding-Mollmann","year":"2004","journal-title":"Deuttsch Medizinische Wochenschrift"},{"issue":"8774","key":"10.1002\/14651858.CD003982.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0140-6736(91)91909-E","article-title":"Overview of azathioprine treatment in multiple sclerosis","volume":"338","author":"Yudkin","year":"1991","journal-title":"Lancet"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD003982.pub2\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,22]],"date-time":"2025-08-22T21:16:26Z","timestamp":1755897386000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD003982.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2007,10,17]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2010,1]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd003982.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,10,17]]}}}